Artelo Biosciences Announces Reverse Stock Split
Artelo Biosciences (Nasdaq: ARTL) announced a 3-for-1 reverse stock split approved by the board on February 27, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artelo Biosciences (Nasdaq: ARTL) announced a 3-for-1 reverse stock split approved by the board on February 27, 2026. The split will combine every three outstanding shares into one and will be effective for trading on a split-adjusted basis at the open on March 10, 2026.
The company said the Board adopted the 3-for-1 ratio to increase the per-share price to improve marketability and liquidity. The new CUSIP after the reverse split will be 04301G706, and there will be approximately 708,258 shares issued and outstanding immediately after the split. All outstanding warrants and derivatives will automatically adjust per their terms.
Positive
- Board approved a 3-for-1 reverse split on February 27, 2026
- Shares to trade on a split-adjusted basis starting March 10, 2026
- New CUSIP 04301G706 assigned after the reverse split
- Outstanding warrants and derivatives will automatically adjust
Negative
- Total issued and outstanding shares reduced to ~708,258 after the split
- Reverse split is a capital action that may change per-share metrics immediately
Details
News Market Reaction – ARTL
On Mar 6, the day this news came out, ARTL closed 2.56% below the previous close.
Data tracked by StockTitan Argus for the Mar 6 session.
Key Figures
- Reverse split ratio
- 3-for-1
- Board-approved reverse stock split of common shares
- Post-split shares
- 708,258 shares
- Approximate common shares outstanding immediately after split effectiveness
- Split-effective date
- March 10, 2026
- First trading day on a split-adjusted basis on Nasdaq
- Approval date
- February 27, 2026
- Board approval date for 3-for-1 reverse stock split
- New CUSIP
- 04301G706
- CUSIP for common stock following the reverse split
- Current share price
- $1.17
- Pre-split price before March 6, 2026 announcement
- 52-week range
- $1.05 – $28.60
- Pre-announcement 52-week low and high
- Market cap
- $2,549,726
- Equity value prior to the 3-for-1 reverse split announcement
Previous Stock split Reports
-
Announced 6-for-1 reverse split to meet Nasdaq bid price requirement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
reverse stock split financial
cusip financial
warrants financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Shares Expected to Begin Trading on a Split-Adjusted Basis on March 10, 2026
SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity. The new CUSIP number for the Common Stock following the Reverse Split will be 04301G706.
As a result of the Reverse Split, each three shares of the Company’s issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the 3-for-1 ratio will automatically be entitled to receive one whole share of Common Stock for each such fractional share. Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the reverse split and no further action is required by shareholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the reverse split. Immediately after the reverse split becomes effective, there will be approximately 708,258 shares of Common Stock issued and outstanding. For further details, all shareholders are invited to review the 8-K regarding this reverse split which will be filed March 6, 2026.
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways, with a diversified pipeline addressing significant unmet needs in anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by an experienced executive team collaborating with world-class researchers and technology partners, Artelo applies rigorous scientific, regulatory, commercial, and treasury management practices, including digital assets, to maximize stakeholder value. More information is available at www.artelobio.com and X: @ArteloBio.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.